New Delhi, Oct. 11 -- The Delhi high court has paved the way for domestic drugmaker Natco Pharma Ltd to launch a generic version of Roche's Risdiplam, a drug used to treat spinal muscular atrophy (SMA)-a rare genetic disorder that causes motor neuron degeneration and progressive muscle weakness.

The Hyderabad-based company, which has a long history of challenging innovator patents both in India and overseas, had alleged that Roche was "evergreening" its patent on Risdiplam in the country.

A division bench on Thursday upheld the March 2025 single-judge order that had denied Roche an injunction against the Indian company, citing public interest, as SMA is a rare disease and wider access to an affordable drug would benefit patients who oth...